AMAG Pharmaceuticals to Buy Stem Cell Company for $700 Million

AMAG Pharmaceuticals Inc., a specialty drug company, said it will acquire Cord Blood Registry for $700 million to expand its maternal health business. CBR houses more than 600,000 preserved umbilical cord blood and tissue stem cell units, more than half of …

[Read the full article here]

Comments are closed.